Atopic dermatitis (AD) is a chronic, inflammatory skin condition driven by complex immune mechanisms involving T cells. In the context of AD, OX40, a costimulatory receptor present on activated T ...

Researchers have systematically elucidated the anti-tumour mechanisms of regulatory T cells (Tregs) for the first time. These immune cells not only suppress pro-tumour inflammation but also enhance ...

APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell ...

Journal Science Advances DOI 10.1126/sciadv.adq8114 Article Title Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells Article Publication Date 10-Jan-2025 ...

Nektar tested the idea in a phase 2b trial that randomized 393 patients with moderate to severe atopic dermatitis to receive one of three doses of rezpeg or placebo. After 16 weeks, Nektar ...

By 2023, the drug had proven its worth in a phase 2 atopic dermatitis trial, leading the pharma to list the anti-OX40 antibody alongside the multiple sclerosis drug frexalimab and the psoriasis ...